SEC Form 4 · accession 0001179110-16-018338
Blueprint Medicines Corp · BPMC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kate Haviland
Officer — Chief Business Officer
Period of report
Feb 1, 2016
Accepted (ET)
Feb 2, 2016 · 6:36 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001597264
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1,F2 | $16.28 | Feb 1, 2016 | A | 100,000 | A | — | Feb 1, 2026 | Common Stock | 100,000 | 100,000 | D |
Explanation of responses
- F1In accordance with the Issuer's equity award grant policy, this option was granted effective as of the first day of the month following the commencement of the Reporting Person's employment with the Issuer on January 5, 2016.
- F2This option vests with respect to 25% of the shares underlying the option on January 5, 2017 and as to an additional 1/48th of the shares underlying the option each month thereafter.